1518 related articles for article (PubMed ID: 30389195)
1. Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE; Patel N; Lu H; Liu Y; Guebre-Xabier M; Piedra PA; Glenn G; Ellingsworth L; Smith G
Vaccine; 2018 Dec; 36(52):8069-8078. PubMed ID: 30389195
[TBL] [Abstract][Full Text] [Related]
2. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization.
Raghunandan R; Lu H; Zhou B; Xabier MG; Massare MJ; Flyer DC; Fries LF; Smith GE; Glenn GM
Vaccine; 2014 Nov; 32(48):6485-92. PubMed ID: 25269094
[TBL] [Abstract][Full Text] [Related]
3. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
[TBL] [Abstract][Full Text] [Related]
4. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
[TBL] [Abstract][Full Text] [Related]
5. Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.
Schneider-Ohrum K; Cayatte C; Bennett AS; Rajani GM; McTamney P; Nacel K; Hostetler L; Cheng L; Ren K; O'Day T; Prince GA; McCarthy MP
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148790
[TBL] [Abstract][Full Text] [Related]
6. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
7. Alternative Virus-Like Particle-Associated Prefusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
Blanco JCG; Fernando LR; Zhang W; Kamali A; Boukhvalova MS; McGinnes-Cullen L; Morrison TG
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511382
[TBL] [Abstract][Full Text] [Related]
8. Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater
Zhao M; Zheng ZZ; Chen M; Modjarrad K; Zhang W; Zhan LT; Cao JL; Sun YP; McLellan JS; Graham BS; Xia NS
J Virol; 2017 Aug; 91(15):. PubMed ID: 28539438
[TBL] [Abstract][Full Text] [Related]
9. Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.
Phan SI; Zengel JR; Wei H; Li Z; Wang D; He B
J Virol; 2017 Oct; 91(19):. PubMed ID: 28747496
[TBL] [Abstract][Full Text] [Related]
10. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age.
August A; Glenn GM; Kpamegan E; Hickman SP; Jani D; Lu H; Thomas DN; Wen J; Piedra PA; Fries LF
Vaccine; 2017 Jun; 35(30):3749-3759. PubMed ID: 28579233
[TBL] [Abstract][Full Text] [Related]
11. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
Hwang HS; Kim KH; Lee Y; Lee YT; Ko EJ; Park S; Lee JS; Lee BC; Kwon YM; Moore ML; Kang SM
Hum Vaccin Immunother; 2017 May; 13(5):1031-1039. PubMed ID: 28129031
[TBL] [Abstract][Full Text] [Related]
12. Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.
Taleb SA; Al Thani AA; Al Ansari K; Yassine HM
Eur J Clin Microbiol Infect Dis; 2018 Oct; 37(10):1817-1827. PubMed ID: 29876771
[TBL] [Abstract][Full Text] [Related]
13. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
[TBL] [Abstract][Full Text] [Related]
14. Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.
Mousa JJ; Sauer MF; Sevy AM; Finn JA; Bates JT; Alvarado G; King HG; Loerinc LB; Fong RH; Doranz BJ; Correia BE; Kalyuzhniy O; Wen X; Jardetzky TS; Schief WR; Ohi MD; Meiler J; Crowe JE
Proc Natl Acad Sci U S A; 2016 Nov; 113(44):E6849-E6858. PubMed ID: 27791117
[TBL] [Abstract][Full Text] [Related]
15. RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine.
Hervé PL; Deloizy C; Descamps D; Rameix-Welti MA; Fix J; McLellan JS; Eléouët JF; Riffault S
Nanomedicine; 2017 Feb; 13(2):411-420. PubMed ID: 27553073
[TBL] [Abstract][Full Text] [Related]
16. Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model.
Kim E; Okada K; Beeler JA; Crim RL; Piedra PA; Gilbert BE; Gambotto A
J Virol; 2014 May; 88(9):5100-8. PubMed ID: 24574396
[TBL] [Abstract][Full Text] [Related]
17. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles.
Rigter A; Widjaja I; Versantvoort H; Coenjaerts FE; van Roosmalen M; Leenhouts K; Rottier PJ; Haijema BJ; de Haan CA
PLoS One; 2013; 8(8):e71072. PubMed ID: 23951084
[TBL] [Abstract][Full Text] [Related]
18. Murine Pneumonia Virus Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus from an Added Gene Is Highly Attenuated and Immunogenic in Rhesus Macaques.
Brock LG; Liu X; Liang B; Lingemann M; Liu X; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925656
[TBL] [Abstract][Full Text] [Related]
19. A Parainfluenza Virus Vector Expressing the Respiratory Syncytial Virus (RSV) Prefusion F Protein Is More Effective than RSV for Boosting a Primary Immunization with RSV.
Liang B; Matsuoka Y; Le Nouën C; Liu X; Herbert R; Swerczek J; Santos C; Paneru M; Collins PL; Buchholz UJ; Munir S
J Virol; 2020 Dec; 95(2):. PubMed ID: 33115876
[TBL] [Abstract][Full Text] [Related]
20. A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.
Rostad CA; Stobart CC; Gilbert BE; Pickles RJ; Hotard AL; Meng J; Blanco JCG; Moin SM; Graham BS; Piedra PA; Moore ML
J Virol; 2016 Aug; 90(16):7508-7518. PubMed ID: 27279612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
